Royalty Pharma PLCNASDAQ:RPRX
- LAST PRICE27.4750
- TODAY'S CHANGE (%)0.2750 (1.0110%)
- Bid / Lots27.4700/ 8
- Ask / Lots27.4800/ 6
- Open / Previous Close27.1200 / 27.2000
- Day Range
- 52 Week Range
- Volume821,058
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | RPRX |
|---|---|---|
| 09:32 ET | 48963 | 27 |
| 09:33 ET | 4023 | 27.025 |
| 09:35 ET | 25920 | 27 |
| 09:37 ET | 8669 | 27 |
| 09:39 ET | 6527 | 27.0047 |
| 09:42 ET | 11564 | 27.05 |
| 09:44 ET | 5133 | 27.085 |
| 09:46 ET | 4643 | 27.075 |
| 09:48 ET | 3167 | 27.07 |
| 09:50 ET | 1525 | 27.07 |
| 09:51 ET | 3208 | 27.105 |
| 09:53 ET | 3651 | 27.115 |
| 09:55 ET | 4712 | 27.13 |
| 09:57 ET | 7955 | 27.11 |
| 10:00 ET | 8876 | 27.135 |
| 10:02 ET | 3498 | 27.09 |
| 10:04 ET | 8357 | 27.135 |
| 10:06 ET | 5368 | 27.13 |
| 10:08 ET | 8203 | 27.12 |
| 10:09 ET | 5335 | 27.115 |
| 10:11 ET | 14020 | 27.14 |
| 10:13 ET | 5666 | 27.15 |
| 10:15 ET | 10031 | 27.135 |
| 10:18 ET | 4937 | 27.09 |
| 10:20 ET | 21312 | 27.07 |
| 10:22 ET | 4904 | 27.08 |
| 10:24 ET | 1759 | 27.12 |
| 10:26 ET | 16852 | 27.16 |
| 10:27 ET | 3698 | 27.155 |
| 10:29 ET | 2318 | 27.12 |
| 10:31 ET | 6779 | 27.1 |
| 10:33 ET | 2289 | 27.11 |
| 10:36 ET | 1654 | 27.09 |
| 10:38 ET | 11071 | 27.125 |
| 10:40 ET | 7296 | 27.175 |
| 10:42 ET | 5819 | 27.18 |
| 10:44 ET | 5689 | 27.175 |
| 10:45 ET | 3421 | 27.21 |
| 10:47 ET | 5746 | 27.225 |
| 10:49 ET | 10750 | 27.215 |
| 10:51 ET | 10089 | 27.23 |
| 10:54 ET | 10259 | 27.2 |
| 10:56 ET | 12869 | 27.215 |
| 10:58 ET | 2913 | 27.21 |
| 11:00 ET | 2342 | 27.205 |
| 11:02 ET | 6651 | 27.18 |
| 11:03 ET | 4390 | 27.18 |
| 11:05 ET | 3836 | 27.185 |
| 11:07 ET | 10406 | 27.195 |
| 11:09 ET | 7545 | 27.2197 |
| 11:12 ET | 2558 | 27.229 |
| 11:14 ET | 8291 | 27.2574 |
| 11:16 ET | 3096 | 27.235 |
| 11:18 ET | 3505 | 27.24 |
| 11:20 ET | 12369 | 27.241 |
| 11:21 ET | 2619 | 27.26 |
| 11:23 ET | 2842 | 27.26 |
| 11:25 ET | 3405 | 27.275 |
| 11:27 ET | 4997 | 27.2864 |
| 11:30 ET | 5789 | 27.29 |
| 11:32 ET | 3986 | 27.29 |
| 11:34 ET | 5140 | 27.305 |
| 11:36 ET | 2461 | 27.32 |
| 11:38 ET | 3656 | 27.3052 |
| 11:39 ET | 3659 | 27.3 |
| 11:41 ET | 2465 | 27.31 |
| 11:43 ET | 2389 | 27.295 |
| 11:45 ET | 2373 | 27.295 |
| 11:48 ET | 2882 | 27.315 |
| 11:50 ET | 2725 | 27.32 |
| 11:52 ET | 6110 | 27.33 |
| 11:54 ET | 1000 | 27.32 |
| 11:56 ET | 1000 | 27.325 |
| 11:57 ET | 1000 | 27.325 |
| 11:59 ET | 2200 | 27.32 |
| 12:01 ET | 5289 | 27.29 |
| 12:03 ET | 4493 | 27.3 |
| 12:06 ET | 5086 | 27.31 |
| 12:08 ET | 800 | 27.31 |
| 12:10 ET | 6049 | 27.31 |
| 12:12 ET | 2971 | 27.305 |
| 12:14 ET | 631 | 27.3 |
| 12:15 ET | 3800 | 27.3 |
| 12:17 ET | 7632 | 27.305 |
| 12:19 ET | 1100 | 27.31 |
| 12:21 ET | 8719 | 27.34 |
| 12:24 ET | 8325 | 27.39 |
| 12:26 ET | 2079 | 27.3974 |
| 12:28 ET | 1500 | 27.38 |
| 12:30 ET | 7190 | 27.38 |
| 12:32 ET | 2626 | 27.39 |
| 12:33 ET | 900 | 27.38 |
| 12:35 ET | 1775 | 27.395 |
| 12:37 ET | 9186 | 27.385 |
| 12:39 ET | 1944 | 27.39 |
| 12:42 ET | 2111 | 27.389 |
| 12:44 ET | 700 | 27.38 |
| 12:46 ET | 5788 | 27.385 |
| 12:48 ET | 1700 | 27.385 |
| 12:50 ET | 3322 | 27.39 |
| 12:51 ET | 5295 | 27.39 |
| 12:53 ET | 2283 | 27.38 |
| 12:55 ET | 700 | 27.38 |
| 12:57 ET | 3667 | 27.41 |
| 01:00 ET | 13007 | 27.45 |
| 01:02 ET | 6344 | 27.44 |
| 01:04 ET | 4900 | 27.49 |
| 01:06 ET | 810 | 27.475 |
Yesterday
Press Release: Royalty Pharma and Syndax Pharmaceuticals Enter Into $350 Million Royalty Funding Agreement for Niktimvo, from 21 hours ago by Dow Jones
21 hours ago by Dow JonesRoyalty Pharma and Syndax Pharmaceuticals Enter Into $350 Million Royalty Funding Agreement for Niktimvo, from 21 hours ago by Dow Jones
21 hours ago by Dow JonesSyndax Pharmaceuticals and Royalty Pharma Enter into $350 Million Royalty Funding Agreement for Niktimvo(TM), from 21 hours ago by Dow Jones
21 hours ago by Dow JonesPress Release: Syndax Pharmaceuticals and Royalty Pharma Enter into $350 Million Royalty Funding Agreement for Niktimvo(TM), from 21 hours ago by Dow Jones
21 hours ago by Dow Jones
Oct 25, 2024
DJ Royalty Pharma Is Maintained at Buy by Citigroup, from 2:37PM ET on Friday Oct 25, 2024 by Dow Jones
2:37PM ET on Friday Oct 25, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Royalty Pharma PLC | 16.1B | 18.3x | +1.83% |
Amneal Pharmaceuticals Inc | 2.6B | -13.4x | --- |
Endo Inc | 1.9B | 0.4x | --- |
Catalent Inc | 10.7B | -10.2x | --- |
Jazz Pharmaceuticals PLC | 6.8B | 19.0x | -3.53% |
Mallinckrodt PLC | 1.6M | 0.0x | --- |
Company Information
Royalty Pharma plc is a buyer of biopharmaceutical royalties and a funder of innovation across the biopharmaceutical industry. The Company collaborates with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. Its portfolio consists of royalties on over 35 commercial products, including Vertex’s Trikafta, GSK’s Trelegy, Roche’s Evrysdi, Johnson & Johnson’s Tremfya, Biogen’s Tysabri and Spinraza, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, Novartis’ Promacta, Pfizer’s Nurtec ODT and Gilead’s Trodelvy, and 14 development-stage product candidates. Its development-stage product candidates include Aficamten, Ampreloxetine, BCX10013, MK-8189, Ecopipam, Olpasiran, Pelabresib, KarXT, Pelacarsen, Seltorexant, Trontinemab, TEV-'749, Tulmimetostat and Vanzacaftor. Its subsidiaries include Royalty Pharma Holdings Ltd., Royalty Pharma Investments and others.
Contact Information
- Headquarters
- 110 East 59th StreetNEW YORK, NY, United States 10022
- Phone
- 212-883-0200
- Fax
- ---
Executives
- Chairman of the Board, Chief Executive Officer
- Pablo Legorreta
- Vice Chairman, Executive Vice President
- Christopher Hite
- Chief Financial Officer, Executive Vice President
- Terrance Coyne
- Executive Vice President - Investments and Chief Legal Officer
- George Lloyd
- Executive Vice President - Head of Human Capital
- Molly Sawaya
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $16.1B |
|---|---|
Revenue (TTM) | $2.2B |
Shares Outstanding | 593.5M |
Dividend Yield | 3.06% |
Annual Dividend Rate | 0.8400 USD |
Ex-Dividend Date | 11-15-24 |
Pay Date | 12-10-24 |
Beta | 0.46 |
EPS | $1.50 |
Book Value | $14.61 |
P/E Ratio | 18.3x |
Price/Sales (TTM) | 7.2 |
Price/Cash Flow (TTM) | 19.2x |
Operating Margin | 42.91% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
